Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Thus far, no study has evaluated the impact on aspirin in addition to the newer and more
potent P2Y12 inhibitors, among ACS patients and current guidelines recommend dual
anti-platelet therapy consisting of aspirin and a novel P2Y12 inhibitor in this population.
Objective The investigators goal is to examine the effect of aspirin in addition to new
anti-platelet agent (ticagrelor\prasugrel) on platelet reactivity in comparison with placebo,
among ACS patients treated percutaneously.
Design The proposed study is a randomized-controlled, double blind trial, conducted among ACS
patients treated percutaneously. Eligible patients will recruited during hospitalization due
to ACS after percutaneous coronary intervention (PCI), and randomization by envelopes on 1:1
basis will take place a month after the index event, at a follow-up visit at the cardiac
clinic.
Platelet function and Endothelial function tests will be taken a month after the index event,
and at a 2 weeks periods following aspirin/placebo therapy, cross-over and return to
open-label aspirin.
End-points platelet function tests will be compared between aspirin and placebo therapy and
before and after the cross-over.